BIOGEN INC.
BIOGEN INC. (BIIB) has a dated report snapshot, but its current priced-in claim is temporarily suppressed because the live engine record is unavailable or has changed.
At about 196 dollars Biogen trades near 11 times operating income, below what even a 5 percent annual profit decline would warrant, so the price embeds contraction even as Q1 2026 non-GAAP EPS rose 18 percent. The growth engines are scaling: Leqembi grew 74 percent year over year to 168 million dollars and Skyclarys 22 percent to 151 million, while the legacy multiple sclerosis franchise declines under biosimilar pressure. Capital allocation has shifted the balance sheet from net cash to about
Is BIIB overvalued? See what's priced in →
971 institutional managers reported holding BIIB in 13F filings for the quarter ended 2026-03-31. Together they hold about 89% of the company; the top 10 hold 55%. 112 opened new positions that quarter. Held by Vanguard Group, BlackRock, PRIMECAP Management, among others. On the short side, 5.2M shares were sold short as of the 2026-06-15 count, about 4% of shares outstanding (5.7 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
BIIB has cut its share count 1.7% over the past five years, spending $1.50B on repurchases. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at BIIB over the trailing three years: 2024: 1 buy totaling $101k; 2025: 1 buy totaling $152k; 2026: 1 buy totaling $1k. 21 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
BIIB's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-02-16 | -6.1% | +6.9% |
| 2023-04-26 | -1.7% | -1.4% |
| 2023-07-26 | -4.2% | -2.9% |
| 2023-11-09 | -8.5% | +10.0% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
BIIB's latest 8-K filings: 2026-07-01 (items 2.02); 2026-06-10 (items 5.07); 2026-05-14 (items 1.01, 2.01, 2.03, 7.01, 9.01); 2026-04-29 (items 2.02, 9.01); 2026-04-06 (items 2.02).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.